Hunter R. Murdock - 20 Jun 2025 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Signature
/s/ Hunter Murdock
Issuer symbol
AXSM
Transactions as of
20 Jun 2025
Net transactions value
-$966,443
Form type
4
Filing time
23 Jun 2025, 19:42:47 UTC
Previous filing
18 Jun 2025
Next filing
27 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Murdock Hunter R. General Counsel C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK /s/ Hunter Murdock 23 Jun 2025 0001934008

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Options Exercise $224,325 +7,500 $29.91 7,500 20 Jun 2025 Direct F1
transaction AXSM Common Stock Sale $768,525 -7,500 -100% $102.47 0 20 Jun 2025 Direct F1, F2, F3
transaction AXSM Common Stock Options Exercise $179,879 +6,014 $29.91 6,014 23 Jun 2025 Direct F1
transaction AXSM Common Stock Sale $602,122 -6,014 -100% $100.12 0 23 Jun 2025 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -7,500 -25% $0.000000 22,383 20 Jun 2025 Common Stock 7,500 $29.91 Direct F1
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -6,014 -27% $0.000000 16,369 23 Jun 2025 Common Stock 6,014 $29.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.
F2 Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F3 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $101.84 and $103.07
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $100.00 and $100.67.